Armata Reports Q1 Revenue of $0.8M, CEO Highlights AP-SA02 Phase 3 Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Reports Q1 revenue $0.8M vs. $0.5M last year. "Our top priority in 2026 is advancing Armata's lead Staphylococcus aureus therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in complicated S. aureus bacteremia," said CEO Deborah Birx. "We are focused on initiating a rigorously designed and operationally efficient study designed to support a future Biologics License Application submission and potential registration. If successful, AP-SA02 has the potential to offer an important new treatment option for patients facing this serious and often life-threatening infection...I also want to highlight other important recent developments including the granting by the FDA of both Qualified Infectious Disease Product and Fast Track Designation for AP-SA02...We are pleased to have the ongoing backing of Innoviva, our largest shareholder who has supported us since 2020, in providing additional financing that will help us to advance AP-SA02, and we are continuing to pursue additional sources of funding, including non-dilutive sources".
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARMP
Wall Street analysts forecast ARMP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.500
Low
9.00
Averages
12.00
High
15.00
Current: 6.500
Low
9.00
Averages
12.00
High
15.00
About ARMP
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Armata Pharmaceuticals Secures $2.5M DoD Funding for AP-SA02 Development
- Increased Funding: Armata Pharmaceuticals has secured an additional $2.5 million from the Department of Defense, bringing total funding for its antibacterial agent AP-SA02 to $28.7 million, reflecting the government's commitment to the program.
- R&D Agreement Continuation: This funding is part of a 2020 agreement with the DoD, which initially awarded $15 million to advance AP-SA02 as an adjunct treatment for complicated Staphylococcus aureus bacteremia, indicating the company's ongoing investment in the antibacterial sector.
- Clinical Trial Preparation: Armata plans to initiate a Phase 3 trial for AP-SA02 in complicated SAB in H2 2026, with the additional funding allocated to essential activities, potentially opening new market opportunities for the company.
- Strengthened Partnership: CEO Deborah Birx emphasized the importance of the DoD's support in the development of AP-SA02, indicating that the collaboration with the government will enhance the company's reputation and influence in the biopharmaceutical field.
See More
Armata Pharmaceuticals Q1 Earnings Miss Expectations
- Disappointing Earnings: Armata Pharmaceuticals reported a Q1 GAAP EPS of -$3.16, missing expectations by $2.78, indicating significant challenges in profitability that could undermine investor confidence.
- Significant Revenue Growth: Despite the EPS miss, Armata achieved revenues of $0.79 million, reflecting a 61.2% year-over-year increase, suggesting improvements in market demand that may lay the groundwork for future growth.
- Potential Risk Warnings: Analysts have noted that while Armata's antibiotic adjunct is intriguing, it carries several potential red flags that could pose threats to the company's long-term development, necessitating cautious evaluation by investors.
- Small-Cap Healthcare Ratings: Following the earnings season, Armata's performance in quant ratings among small-cap healthcare stocks has been lackluster, potentially leading to lowered market expectations for its future performance and impacting stock price movements.
See More
Armata Pharmaceuticals Secures $25 Million Loan to Advance Phage Therapy
- Financing Support: Armata Pharmaceuticals entered into a secured credit agreement with Innoviva for a $25 million loan maturing in 2029, with proceeds aimed at advancing the development of AP-SA02, demonstrating the company's ongoing commitment to addressing antibiotic resistance.
- Clinical Trial Progress: The Phase 3 superiority study for AP-SA02 is expected to initiate in the second half of 2026, targeting complicated Staphylococcus aureus bacteremia, and if successful, will lay the groundwork for a future Biologics License Application (BLA).
- FDA Fast Track Designation: AP-SA02 has received both Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA, which will expedite its clinical development and approval process, enhancing patient access to this innovative treatment option.
- Financial Performance: In Q1 2026, Armata reported a net loss of $115.3 million, or $3.16 per share, reflecting increased R&D expenses while the company actively seeks additional funding sources to support its ongoing development efforts.
See More
Armata Receives FDA Fast Track Designation for AP-SA02
- FDA Fast Track Designation: Armata Pharmaceuticals' AP-SA02 has received Fast Track designation from the FDA, marking a significant advancement in the treatment of antibiotic-resistant bacterial infections and is expected to expedite the clinical development and approval process.
- Clinical Study Plans: The Phase 3 superiority study for AP-SA02 is anticipated to begin in the second half of 2026, aiming to evaluate its efficacy against complicated Staphylococcus aureus bacteremia, potentially providing new treatment options for patients.
- Funding Support Background: The clinical development of this project is partially supported by a $26.2 million Department of Defense grant, highlighting government emphasis on the development of new therapies and providing robust financial backing for Armata's research efforts.
- Market Demand Response: The Fast Track designation for AP-SA02 not only reflects the seriousness of complicated Staphylococcus aureus bacteremia but also underscores the urgent market need for effective new treatment options, which may enhance Armata's competitiveness in the biopharmaceutical sector.
See More
Armata Pharmaceuticals Q4 Earnings Report Analysis
- Poor Financial Performance: Armata Pharmaceuticals reported a Q4 GAAP EPS of -$3.42, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Revenue Decline: The company generated $1.1 million in revenue, an 8.3% year-over-year decrease, reflecting weak product sales and the potential need to reassess market strategies to restore growth.
- Cash Flow Situation: As of December 31, 2025, Armata held approximately $14.1 million in cash and cash equivalents, down from $14.8 million in the same period of 2024, indicating liquidity pressures that may affect future operations.
- Uncertain Market Outlook: While Armata has potential in the antibiotic adjunct space, there are numerous red flags regarding its future development, which may lead to investor concerns about its long-term value.
See More
ARMATA PHARMACEUTICALS INC REPORTS Q4 2025 NET LOSS OF $3.42 PER SHARE
Company Overview: Armata Pharmaceuticals reported a net loss of $3.42 per share for the fourth quarter of 2025.
Financial Performance: The significant loss indicates challenges in the company's financial health during this period.
See More
Armata Pharmaceuticals Secures $2.5M DoD Funding for AP-SA02 Development
- Increased Funding: Armata Pharmaceuticals has secured an additional $2.5 million from the Department of Defense, bringing total funding for its antibacterial agent AP-SA02 to $28.7 million, reflecting the government's commitment to the program.
- R&D Agreement Continuation: This funding is part of a 2020 agreement with the DoD, which initially awarded $15 million to advance AP-SA02 as an adjunct treatment for complicated Staphylococcus aureus bacteremia, indicating the company's ongoing investment in the antibacterial sector.
- Clinical Trial Preparation: Armata plans to initiate a Phase 3 trial for AP-SA02 in complicated SAB in H2 2026, with the additional funding allocated to essential activities, potentially opening new market opportunities for the company.
- Strengthened Partnership: CEO Deborah Birx emphasized the importance of the DoD's support in the development of AP-SA02, indicating that the collaboration with the government will enhance the company's reputation and influence in the biopharmaceutical field.
See More
Armata Pharmaceuticals Q1 Earnings Miss Expectations
- Disappointing Earnings: Armata Pharmaceuticals reported a Q1 GAAP EPS of -$3.16, missing expectations by $2.78, indicating significant challenges in profitability that could undermine investor confidence.
- Significant Revenue Growth: Despite the EPS miss, Armata achieved revenues of $0.79 million, reflecting a 61.2% year-over-year increase, suggesting improvements in market demand that may lay the groundwork for future growth.
- Potential Risk Warnings: Analysts have noted that while Armata's antibiotic adjunct is intriguing, it carries several potential red flags that could pose threats to the company's long-term development, necessitating cautious evaluation by investors.
- Small-Cap Healthcare Ratings: Following the earnings season, Armata's performance in quant ratings among small-cap healthcare stocks has been lackluster, potentially leading to lowered market expectations for its future performance and impacting stock price movements.
See More
Armata Pharmaceuticals Secures $25 Million Loan to Advance Phage Therapy
- Financing Support: Armata Pharmaceuticals entered into a secured credit agreement with Innoviva for a $25 million loan maturing in 2029, with proceeds aimed at advancing the development of AP-SA02, demonstrating the company's ongoing commitment to addressing antibiotic resistance.
- Clinical Trial Progress: The Phase 3 superiority study for AP-SA02 is expected to initiate in the second half of 2026, targeting complicated Staphylococcus aureus bacteremia, and if successful, will lay the groundwork for a future Biologics License Application (BLA).
- FDA Fast Track Designation: AP-SA02 has received both Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA, which will expedite its clinical development and approval process, enhancing patient access to this innovative treatment option.
- Financial Performance: In Q1 2026, Armata reported a net loss of $115.3 million, or $3.16 per share, reflecting increased R&D expenses while the company actively seeks additional funding sources to support its ongoing development efforts.
See More
Armata Receives FDA Fast Track Designation for AP-SA02
- FDA Fast Track Designation: Armata Pharmaceuticals' AP-SA02 has received Fast Track designation from the FDA, marking a significant advancement in the treatment of antibiotic-resistant bacterial infections and is expected to expedite the clinical development and approval process.
- Clinical Study Plans: The Phase 3 superiority study for AP-SA02 is anticipated to begin in the second half of 2026, aiming to evaluate its efficacy against complicated Staphylococcus aureus bacteremia, potentially providing new treatment options for patients.
- Funding Support Background: The clinical development of this project is partially supported by a $26.2 million Department of Defense grant, highlighting government emphasis on the development of new therapies and providing robust financial backing for Armata's research efforts.
- Market Demand Response: The Fast Track designation for AP-SA02 not only reflects the seriousness of complicated Staphylococcus aureus bacteremia but also underscores the urgent market need for effective new treatment options, which may enhance Armata's competitiveness in the biopharmaceutical sector.
See More
Armata Pharmaceuticals Q4 Earnings Report Analysis
- Poor Financial Performance: Armata Pharmaceuticals reported a Q4 GAAP EPS of -$3.42, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Revenue Decline: The company generated $1.1 million in revenue, an 8.3% year-over-year decrease, reflecting weak product sales and the potential need to reassess market strategies to restore growth.
- Cash Flow Situation: As of December 31, 2025, Armata held approximately $14.1 million in cash and cash equivalents, down from $14.8 million in the same period of 2024, indicating liquidity pressures that may affect future operations.
- Uncertain Market Outlook: While Armata has potential in the antibiotic adjunct space, there are numerous red flags regarding its future development, which may lead to investor concerns about its long-term value.
See More
ARMATA PHARMACEUTICALS INC REPORTS Q4 2025 NET LOSS OF $3.42 PER SHARE
Company Overview: Armata Pharmaceuticals reported a net loss of $3.42 per share for the fourth quarter of 2025.
Financial Performance: The significant loss indicates challenges in the company's financial health during this period.
See More
